Lirum Therapeutics Past Earnings Performance
Past criteria checks 0/6
Lirum Therapeutics's earnings have been declining at an average annual rate of -14.7%, while the Biotechs industry saw earnings growing at 14.7% annually.
Key information
-14.7%
Earnings growth rate
8.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -92.1% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Lirum Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -2 | 0 | 2 |
| 30 Sep 23 | 0 | -4 | 0 | 3 |
| 31 Dec 22 | 0 | -2 | 0 | 2 |
Quality Earnings: LRTX is currently unprofitable.
Growing Profit Margin: LRTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if LRTX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare LRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: LRTX has a negative Return on Equity (-92.09%), as it is currently unprofitable.